{"success":true,"data":{"pressRelease":{"id":"156480","rtpr_id":"nPn6TPKpZa-20260930","ticker":"CTSO","exchange":"NASDAQ","all_tickers":["CTSO"],"title":"CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care","author":"PR Newswire","published_at":"2026-09-30T11:00:02.859Z","article_body":"CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care\nPR Newswire\n\nPRINCETON, N.J., Sept. 30, 2026\n\nPRINCETON, N.J., Sept. 30, 2026 /PRNewswire/ -- CytoSorbents Corporation\n(NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in\nthe intensive care unit and cardiac surgery using blood purification,\nannounces upcoming data presentations using CytoSorb® in open heart surgery\nat the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting\nin Barcelona, Spain from October 7-10, 2026 and in critical care at the\nEuropean Society of Intensive Care Medicine (ESICM) Annual Congress in Lisbon,\nPortugal from October 10-14, 2026.\n\nUpcoming International EACTS and ESICM Conferences Highlight CytoSorb Use in Cardiac Surgery and Critical Care\nEACTS 2026\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=865241141&u=https%3A%2F%2Fwww.eacts.org%2F40th-eacts-annual-meeting%2F&a=EACTS+2026)\n is the world's largest cardiothoracic surgery conference, focusing on\nadvancements, innovations, and surgical techniques for heart and lung\nconditions.  The following data presentations highlight the use of CytoSorb\nin cardiac surgery:\n\nThursday, October 8, 2026:\n\n * Intraoperative Hemoadsorption to Reduce Bleeding in Isolated CABG under Dual\nP2Y(12) Inhibitor and DOAC Therapy\nProf. Michael Schmoeckel (Ludwig Maximilian University (LMU), Munich, Germany)\n * Hemoadsorption for Postoperative Vasoplegia: Real-World Data from the\nInternational Prospective COSMOS (CytOSorb® TreatMent Of Critically Ill\nPatientS) Registry.\nProf. Federico Papallardo (San Raffaele University, Milan, Italy)\n * Hemoadsorption to Reduce Hyperinflammation during VA-ECMO: Results from the\nInternational Prospective COSMOS Registry.\nProf. Federico Papallardo (San Raffaele University, Milan, Italy)\nFriday, October 9, 2026:\n\n * Improved short– and long–term outcomes in 'high–risk' heart transplant\npatients with adjunctive intraoperative hemoadsorption treatment – A single\ncentre's decade of experience\nProf. Endre Nemeth (Heart and Vascular Centre, Semmelweis University,\nBudapest, Hungary)\nESICM LIVES 2026\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=1068558133&u=https%3A%2F%2Fwww.esicm.org%2Fevents%2F39th-annual-congress-lisbon%2F&a=ESICM+LIVES+2026)\n is one of the leading international critical care conferences highlighting\nthe latest research, guidelines, and treatments in intensive care medicine.\nData from the COSMOS Registry will be presented by Prof. Ricard Ferrer (Vall\nd'Hebron Hospital, Barcelona, Spain).\n\nMonday, October 12, 2026\n\n * Liver Support with Hemoadsorption: Initial Report from the International,\nProspective COSMOS Registry\n * Hemoadsorption to Treat Hyperinflammation During VV-ECMO: Preliminary Report\nfrom the International COSMOS Registry.\nTuesday, October 13, 2026\n\n * Hemoadsorption for Postoperative Vasoplegia: An Analysis from the\nInternational, Prospective COSMOS Registry.\n * CytoSorb hemoadsorption as an adjunctive treatment in sepsis and septic shock:\nInsights from the first 200 patients included in the international,\nprospective COSMOS Registry.\nDr. Phillip Chan, Chief Executive Officer of CytoSorbents, stated, \"We are\npleased to see such a broad body of clinical data on CytoSorb accepted for\npresentation at two of the world's leading cardiac surgery and critical care\nconferences.  These presentations span important areas of unmet medical need\nacross cardiac surgery - including the removal of blood thinners, heart\ntransplantation, heart failure, and shock following open heart surgery - as\nwell as critical care applications such as acute liver disease, acute\nrespiratory distress syndrome (ARDS), and septic shock.  The latter is\nparticularly timely as Sepsis Awareness Month draws to a close and reinforces\nthe continued need for more powerful approaches like CytoSorb to help manage\nthe life-threatening hyperinflammation and organ dysfunction associated with\nthis devastating condition.\"\n\nDr. Chan concluded, \"We remain deeply committed to supporting high-quality\nclinical research and expanding the evidence base for CytoSorb across a wide\nrange of deadly conditions.  A cornerstone of this effort is our\ninternational, prospective, multicenter COSMOS Registry, which is designed to\nsystematically capture real-world clinical experience with CytoSorb across a\nbroad spectrum of critically ill patients.  By generating data on how\nCytoSorb is being used in everyday clinical practice - including patient\nselection, timing and duration of therapy, safety, and clinical outcomes -\nCOSMOS is providing important insights that complement controlled clinical\nstudies, help clinicians further refine and optimize CytoSorb therapy, and\nhelp to further establish the role of CytoSorb in the management of complex\ncardiac surgery and critical care patients worldwide.  We are excited to see\nthis growing body of evidence being shared with the international medical\ncommunity.\"\n\nAbout CytoSorbents Corporation (NASDAQ: CTSO)\n\nCytoSorbents Corporation\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=3361727760&u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D9JuP_ayC1LdGvZSRsWbpOcxv8qk6wGLsY2t00RIQUOzAH3VW97AvfsG_ahhmT0mys1Z7mMogHwGPt5_roawj-VjXMApe7mJPp3JTGiiEMRssOYDddfH8wccpgiHMCPcv-2cDU61vi58bwv5dHDhj7peoy1MZKZWlCXfz1_N9E3t0HjjPmVOwadc3qZ-Ve58qLcX37ZTHWslNYdMBkXhoIeyZXNyYDOo4OgcYt9s3LH6JIp5Q4wqFW8nd_3bcUoKKVTzA_KymPoJJgOppVrLNTA%3D%3D&a=CytoSorbents+Corporation)\n is a leader in the treatment of life-threatening conditions in the intensive\ncare unit and cardiac surgery through blood purification. CytoSorbents'\nproprietary blood purification technologies are based on biocompatible, highly\nporous polymer beads that can actively remove toxic substances from blood and\nother bodily fluids by pore capture and surface adsorption. Cartridges filled\nwith these beads can be used with standard blood pumps already in the hospital\n(e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal\nmembrane oxygenation or ECMO, and heart-lung machines), where blood is\nrepeatedly recirculated outside the body, through our cartridges where toxic\nsubstances are removed, and then back into the body. CytoSorbents'\ntechnologies are used in a number of broad applications. Specifically, two\nimportant applications are 1) the removal of blood thinners during and after\ncardiothoracic surgery to reduce the risk of severe bleeding, and 2) the\nremoval of inflammatory agents and toxins in common critical illnesses that\ncan lead to massive inflammation, organ failure and patient death. The breadth\nof these critical illnesses includes, for example, sepsis, burn injury,\ntrauma, lung injury, liver failure, cytokine release syndrome, and\npancreatitis as well as the removal of liver toxins that accumulate in acute\nliver dysfunction or failure, and the removal of myoglobin in severe\nrhabdomyolysis that can otherwise lead to renal failure. In these diseases,\nthe risk of death can be extremely high, and there are few, if any, effective\ntreatments.\n\nCytoSorbents' lead product, CytoSorb\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=3786967255&u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D9JuP_ayC1LdGvZSRsWbpORxGgG5d5RRi3BuX6LwmaJVAb04b6VxEP2rIDiYKjhRY5BGBnQuM6Q3kjTT1kfgmJGPxn9msqMZmf55jsQLSmKJgQTCQc49wvOWphERpmow-P87r7PViCzBb4Y1ZEzd5znEqmX1WUt1VTubl-o_XzoOUQxKPV1ejae2pzOWyPwo54Zr0G8HPM_KqCP8VP6Oi33ltMv4kDPIEX-iy4QoeMCsq3ZZr5KMFbJ6fBk9OngDF1tAOdFdSa6W_409-5F4-nFkP2EoLIZZPwTw-DKcZROoiFjY4tWzcmuV7qhq5LUUsQhRZ3ZAv9nDI97f4WQJ0zLoh4-r4UlAokT4cYtVx4F6tYd5dNSNSUb9Iyhc68l340zD8UOZt65d8NH0gcJyrO8V8lN3U2xWVmg3xmZPrdQM%3D&a=CytoSorb)\n(®)\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=293165892&u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DbaBPxM0OpouV4xBPdNuHYQfGlZzkY6K_qG46Q_IfgFR7arUisOobkA4cKQtSOQe-rOZwkkPdbDu0IgqPxsa3VLymjAokxa4qRMDc_fjcjL96L8-mdjI6ris1lWrtE8SBx43Dfm8nQT3BrsqC0kmhkT93ee-edDa032oIFBytvd__bccMenYfVeHvDkWY5G6WKhb_hAPt1ZDUOfDAHd_qY7W-sp6_0ILjoK7fshGy3IaCnVA6i42GWSj8gPbkimYNrkj5Qbsv4HWv0gIxibWQdHL8pgVjyUx-Eji5ostWKueYyoNF80xmsKMYMH5wRWhD2ggm8zuuzSXYU3SqdBRRB9LgsaCixpvGzMWcWwkEzfhQr32x4ogyvmWyS2yz0UfUE1F25JKP8VQFnxtCNIPX0zmBswRbttO6WNcl5IzNMKs%3D&a=%C2%AE)\n, is approved in the European Union and distributed in over 70 countries\nworldwide, with more than 300,000 devices used cumulatively to date.\nCytoSorb was originally launched in the European Union under CE mark as the\nfirst cytokine adsorber.  Additional CE mark extensions were granted for\nbilirubin and myoglobin removal in clinical conditions such as liver disease\nand trauma, respectively, and for ticagrelor\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=135522112&u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DBevZEUStHG2IGGo9anAX_kSPtnFrGz8ipiosqgiTXfKw3qMh-1zNEzD9J5E3RekPKCTE-y4C_wqlKR9OVFfNam6JivDoyEJq9TOmJbNtSM_s6u3J0KUzy0xeXAWsqydOQ92QyjhKhSinO6Gc7atcfWLADoAceyiakLu2G9QTXTlVw0OZwXiMVuyw7Cs-Ecaz0s1_fAOQaCqgeR_nCsu6Zx-7NNBmsaCYsctLsuJFh6ZJcKCFc2ZLMBH7fwvz3WQicCKLtGj29GVMBG0NasMP1FD47T7pPJz7HryVVqXdT-h7Sn515aPzGZT_cxLdRgbbvTKHF-jIiK6hN6KhFTcqs4Y-1XZADWNIKvQ7kCz-4_WrHaFKEkeE5YzTV-37oek5advSjnyuNsq6CLS3ObvS25khvux6rg-8msBJ6R6ULEUzdbyR0PTYCvqYvA8M9Y9H9dIRNnh27YgzCedTKhdDRm3tJCxmTnyRgYJ_TiUP92_ildMETnXAexElnRbsADbkpbOMOBgpXDEEuc1aySo2TEC91JyCM_BOZF3bHq5PjpP2vK1phXPmYaA8gKD6To0oPdzHfOKEEnHMLxeq_8McvrH-KoanI3LwVurLwV4IDBZm1okXjoQB81Tktr3F2hn7AlqVJsyy4wf3-OBbwxlLtN4my1RtRykA6CaYvX2b0HeDuPBOeXvrKlvOrgcUQYvUsICM9i63gvrVBV11PTn1_EgnEwV-qgj3_iEuoqsE-F8qDFpRwl4N7R4Ob8L_-ApAZrNVNIofvB5oDpym63X0Aw%3D%3D&a=ticagrelor)\n and rivaroxaban\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=2712168254&u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3Dp47WrgYj8pmjYpAToXFgCBnYjnYobpTSHcu-db0NjHxVTyhpykBGcN6QCaM1R6hx33XBIndzInv4GO1RZoDg9SgJvKPmJjB6r7Kr9oCGCUVfQAWl_WP2JV8PblJXBmgLZfQk4cji55Tzbj3rMvIqVx-RNfHAwpxZPcsXWYxIbsAO4mHmlB0-RdTJDSrpZr20lyzVVmV7jh2CY7xvKtyPo6q4DNWunLrC6S5nYmqReatahfVYT6XMCCk1Y-jIv--09ysz652OrQbnfPGBOpeldNxKRA2uzZReWbvfOnn3rNsQ4QbXvXOf2DwvJWVo2JWl05tCR7JQvF87Tt00bLnfiYdmrFJegNei1CwN-G-poPHXnzp3tajndqz7lUxgs9rh8yWvU41XhRN9PyPJnkBsckHMSEDiH9uwP8g5cTQ_DPKcSwfMBo0S_Z32D0qqrdGUfE3HecdsgOanxffcpBxZOVb6_ONPyJLBB81v7of7Mcnl2U8zG4bPvikILAbdljD5dpWIvxsSk8eYN_wwAGPVwuIlEKsQDg2zUFzoWptwzTXKscjE68FBj6kM8t_9tGMCf4MoNIojWGsdX00wasx2K8c46_ig0E-RcxGAIa_ce4VQ42L_7ehyeaNlrtoZjqm5gJf1c5-UMIZ4qPtRt-GOt0-NqGzlWIesspUjNBnm9b2dZHDFzHbIYkSk_qk8BALJzyV9SiiuXog-OmC075Pgt1Qb586C-c4tf-aV9zFBey0X3bmJKxjeYES8bEziGcia7MK85FFCxPFbl7K6njmB5gHvTro8Qm3RoaxO0rsE8CaOcc3bdCFZGEJiSFPq4c-k&a=rivaroxaban)\n removal in cardiothoracic surgery procedures. CytoSorb has also\nreceived FDA Emergency Use Authorization\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=307639980&u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3Dm2FNhPcJgHNCmRfLJVv2QaAW1tb2zXDzuMyJsT4OyY05SQFzpVg7VpryNSG_1ORQ3MnpsEhyG8-uJcHJwbmf-YrAF0xdBIjMjHeE_-RbhLlxJXUYoNTG7-i2BFq6mE_3BR9lM-cyxeoPxQ8HSRVpEKZnFLf2iMp_EAjk81MLks2pp3BEPxXDg7GB8hWbWqmyEKPPOGyLg6KcQEgnq1mE-lYmkOWcZTQGWHRs7hyQeCWvm8wzHp7_-0t-GCiKaMhT76JaGuu8StI7n8bXuFfDHzO-k09EXhw5KftVKx3rGA1oeNE-oi4X3-sUrSW66jed-XUIzr5kbb6BlqcnHnShdWzbWUpSyr4Z-HGvs6H9gxx_IsW6S-XdIlg9fhtZbGNHDXyVeGym1Zgymgr16oO2XAO58RAP1-TM5pq9kjItAFFm6yDMHNv4d72c93d8jNMcSaKg2WquKvQNApj68hp_p-C69ojr1P7JX4lnHeVSFp2gJO2IdQoNBHu8TNMiQHrZXAobag-FEX0EaUdsb6S9ZJaTaZb3e4BNlN7Ae40qnjQgonSqF4K185b-ayMm3GuU02bsTFvdQZngRu65EqfK1MibhcuQXEv4-nulswtMGJsmLW7iMPrOuYHXkmZKwzn1WBMWaviYa8t9K_AvB7dkkEW7OrNN-bAhwG1tyoz695kAOwdnL0yEGS0LjB8bxDFivx-X7ZE8XzdwDP7UXuF2GonsCc1MWlwUskFiMZDFgYjg1mvJy3q3FA8V5amSK3jlJ-3DAvrirP9meVVBdXETJZ75k3u7SSgVstNgfmdVujRiw8Lx0j1Q9pnLI3nUv-BJ&a=FDA+Emergency+Use+Authorization)\n in the United States for use in adult critically ill COVID-19 patients\nwith impending or confirmed respiratory failure.  CytoSorb is not yet\napproved or cleared in the United States.\n\nIn the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR\nantithrombotic removal system, an investigational device based on an\nequivalent polymer technology to CytoSorb, to reduce the severity of\nperioperative bleeding in high-risk surgery due to blood thinning drugs.  It\nhas received two FDA Breakthrough Device Designations\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=1252299118&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4492043-1%26h%3D2476011309%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4484224-1%2526h%253D3712982973%2526u%253Dhttps%25253A%25252F%25252Fwww.globenewswire.com%25252FTracker%25253Fdata%25253DOVYNYVfVfZTwSB92O9_yJfhu9YsEcpW6lg6ML5vFCptxR44HDP4r6iT5zmJIIfYbxtpoGxotkZNp5WaA2UFp1BzONSEbP-JnxHDsgt_gqku1bWgZzGxpI6Bxy8IHho1GqBkd8dOKS5U2dX7yTgyMHhBD0fGGQ7lczyR_AZk-JS7x-pT_Bqfb2q2MCuc_Qt2Mgs9FkyR_XSHYG4OWBARA8nhLNtL_SvM9NL2O5rGboN8Krvuu6TNd02rb6wNKMfGErajMJbU8hamDo_tF2JVs7N27aOWiotz4FJeXcF4bPQVVdJPKLH9egCJziSVHtGjwWhwaKw1EU9j3QZ5Bj2AHo97lCl2HlB61jk9tcuabeb6hR2hJ_ugB8WUJ83E8XMXRqYvo6LvvS5HBmfJqo_vB2_yXUFwd0yCbRXiT6L0CCDpPZ1f46lUOhY7z1OhPY7_1VYEgMEZEvF7tYM08bZal17zyoqqedwkMRD4RQXmtNHMkc8_ydS4LtafjfDjtmlL6HPVYSK2x1Gt8Dm7Fv3yq4jEVuaYH2nwTMW_K7xatC6REaGB7565Mrg874XTgtGVJAWShOhSnFlTENjl80p9FSbQ54XiM9dN2w8IU9C5NAZbkXBtmLIkAcPO9EhMzW7AMp9nYsnXUBV3_iPoGb6tI-x6ytgcXVvacsFcOxZ2SGuKaRZUGawbo3Zx0R-E2rV5wkF2ckzdhToMrrBMGUNNTNfrR0geKm1pP2Sg8gDIz_SLTC6s10f6OOfVZutP_5a2dw66GfdjNZZZASjInAJRph3BAEbwo-4tb76befGMf1IDNhIXOvxRIOmULbFbaBemQ_wN52soeFXg5vuB1PCk5udsH_J8jD4brC_t_E_UNh-sSAQzUyp7x0fXOvc55-jPBVJC_KCp5TiTEpdI2j_vXLqzKS_PmazRaGRzVE9ItMAsNXP4mP4AHMf7oenhGU282VnKAcErxSOMWrkGwOhs2XjM6EU5ux5yK1n8jMGmyaSfoAQOpybL1IClQ0_e1r6zu%2526a%253DFDA%252BBreakthrough%252BDevice%252BDesignations%26a%3DFDA%2BBreakthrough%2BDevice%2BDesignations&a=FDA+Breakthrough+Device+Designations)\n:  one for the removal of ticagrelor\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=579167168&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4492043-1%26h%3D2072534648%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4484224-1%2526h%253D182667382%2526u%253Dhttps%25253A%25252F%25252Fwww.globenewswire.com%25252FTracker%25253Fdata%25253DBevZEUStHG2IGGo9anAX_sK9FUmyXMo-P_MG36LpTYuG9ZUwyu7QHdXrf2ZKHbGYg4QNgsvM_gaUcmF5yklQp76iKyqOa_ddZRkBt2kRe7sC5GMbetFomKR2KWFAWOFoY5jNT4U3DHMBT9NHx4j8yO6EzDGETQTIpUmMFGySVexqa4A_PbM6jaQzEkluS4lZYntV9NN4bXRs4SPlEwUSqXroetgS_yayRqGOBHOLstwRhaFyXWcCHd4inwMm54ZE31Rmz8dBZgdcu-BRspFBE3akThhcKY0gBTYBYVSHjnCdAo5qmkv8hkWMY2G5hXVRZm2JYyraZMssywdnVF5F0CHpRAFwGEwMWE2Njj1Pt52Mo1lc3INMrhBmWDA-NmC9LEA9QwqVa46A60NbMod6s4hqQLotRCWof5KZglqdYXgC6aGeQ6hTa1ayTsYgzwiGk_tMsWUj525w4lLPPmgf3VVfvQXMrMt02b_zkMIHbZl1seiYnLx2OZZ8Dkfmzj6RtxYGZRXDgXDUE1iuVy6f0pDPoydYexYuEUvNsJ_kE99TyDpaDGuNZbtnqjCukU_X2uFDD3coXNrgGLPa-uRL3fB9B3ko7V2dTDgIZWilIpIgnatnUA-4w8Q4Dr5ZMTLqejY18puoTORponx08v437S2gIJE-PFee2zYXeJVYsfLoi5sFzFWqsrbHCHKnSJsSawGpFpdW7GT7C0rIeSwiAKlIrBE9eAQqsM-G8I70LyU6MZ2Suywae6f4rmyG6ZTAsB29xoKVR_RyrC-m4Yb8gvmrsfx4IVU0MW5MSq6lFQAX-rHR0c1yFB1abbOb3H97_ZvJC8ZJIDgiE61FVI0ehagjW7Q1rS51KqAqxNasQWSq-BaxNEeYLSrrFU552ZZD_-eKvUwlqhE7ivtmz05hiw%25253D%25253D%2526a%253Dticagrelor%26a%3Dticagrelor&a=ticagrelor)\n and another for the removal of the direct oral anticoagulants (DOAC)\napixaban and rivaroxaban\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=2175267183&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4492043-1%26h%3D1768743861%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4484224-1%2526h%253D2278238800%2526u%253Dhttps%25253A%25252F%25252Fwww.globenewswire.com%25252FTracker%25253Fdata%25253D2qt5UxRbkefI_XwOXSqhA9q3FRJO4rv6H0__RAcvJtHWtIQeDwRE9RPGavd8-FcYqZAgy_vbeVwCWXlW4lGJ4ToTpGPq7AbbAEEKKGQFf8Pdg0EL0Dx0dn-5MH54wYgpVDUNT_RVHrdrj2dNiGCcPyOI3Lt5dUauPucTliFxodbC_ilzsO0qoWvBDY86aPH9s5HiXIvDP0Q0pcaILyeq3SvA2rhfo5M8oKbPGxwf7yajJBkQBKDyO0snrFWdLSh4fUlwEQMAIkSsYc48fSYvt21Ow3ljvmtUsSzZYqxvaEcS4qtaYXp0ztWd56XLVcLdE16GKjuBg3O9t6JeazAcWikCLHUBhbGxLKlkjaGZ-Edj0uxCOsC2fivgDUmid_d3N7IxMdopzznesT-Puyq3hZnwwG9J_UBQRWLfxuoqb1skPw5MSYR0J4izvHJkaUnuojNOdvQONtb_sIujI7A2hDFwbj0WODj7OprKHLDzNqRgw6T3MFRNWPGXTpxABWqWZ_GbEgUnF4kKfOmruUrVicFcpNWuyKrYS2a_mRDxZVjLF-VX8jmYe2mJ4n43H6ybnzFk8XeLxYBXaSzHdObYs6y9dkJ8Hwo5CrhKLznklX7DdoPvRyLY2xrnJf2dXIVyd03Wmsk0aOHffU_F8Z4fDkOjA97HQT11yVdReAcr1BwPS4pYPw2u5mKIsQlHd3OilyMVLfUQoie7mDUiLFns-CrIEoQ-mXDgoNulMDoIndvua3-dc8b6McLa5djidyYox4GWjovVTu_Beu0m0mt-6BsEFyKKURkmSdQe0uq78VtRdp9cBry4n-LRHcUz35dC-RfbEo7HL2dHS4CLnhn4KBfhCDpty6ukqhF5AbHxP9P39TM5_jbFrbNcdJ0USCdjUfwaHgzD0tali0mjBesnBtNG29aG2ikR1HPAW1fbouxtF9CsD-qhJ0KSiGRoL_avZDZI2DN3u7vn5c2NVazCMWATGVqOza8umQ_r0u4tCdv3qfrreEYDshwRLyJuIu5b7Uy1sB0dERGVHnML3KGewYgO6Sb-bpEEyL_HuQAKe17KsHeEERmwmrFKQs5iXv2IWU2u8cWQVOGEsD-4wms94t5gnUD2vt7RH1UcuyjYq9cwIpz7Y34pSY5RL_FBk69QJ4GnKifnRu8ggIK4Is_l20ecwTdmPyOQVqWcmNnu_AYYwpSRIHPT6sLK3M4BTSlnzmuTQywWbmDCJ_494lng6rZ_X_3wgSRqvhz6iRtOChA%25253D%2526a%253Ddirect%252Boral%252Banticoagulants%252B(DOAC)%252Bapixaban%252Band%252Brivaroxaban%26a%3Ddirect%2Boral%2Banticoagulants%2B(DOAC)%2Bapixaban%2Band%2Brivaroxaban&a=direct+oral+anticoagulants+(DOAC)+apixaban+and+rivaroxaban)\n in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery.\nThe Company is actively pursuing regulatory approval of DrugSorb-ATR with the\nU.S. FDA and will pursue regulatory approval with Health Canada with better\nvisibility from the FDA.  DrugSorb-ATR is not yet granted or approved in\neither the U.S. or Canada.\n\nThe Company has numerous marketed products and products under development\nbased upon this unique blood purification technology protected by many\nissued U.S. and international patents and registered trademarks, and\nmultiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™,\nHemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™,\nContrastSorb, PuriFi®, HotSwap®, and others. For more information, please\nvisit the Company's website at https://ir.cytosorbents.com/\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=1468745960&u=https%3A%2F%2Fir.cytosorbents.com%2F&a=https%3A%2F%2Fir.cytosorbents.com%2F)\n  or follow us on Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=1391433662&u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DsB2AG7X4Z43BoIDfgybXOhtx6hajGmLFRYdf-CJkEqF3K0BxaD2m7c_NZkYwFsYeNOY-LK22UCYVjieKWHZcgsLvVcrOalL0DfCSkqBZ2R_uGHEIFHLoP0BQqxUZI_ekbspxc47A02TOAJxuUO_K9TZyQwpeGoQum9SjiTg36Arl4PtOgWHHT25tP3a7Ym1EB8iQrlZmSYoiowd-zHbIFTmyj_pRohZ2MNAXPml_QnQFTso55cgXNSvoEGmuwOjL&a=Facebook)\n and X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=4098877400&u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DKRERF9IW2qXW13jmGfo2v9T8dZnx2rVmbAIsoapwSyctLh6P5jlWX3C4X5SXqbzb0GaZHZ5_z5G5t0Zl0IzRFWQlon1TY5bfeIRgjKiElxVuahzWnjosldeOn5JOUPxhCbumHzexqM_fZKIwMl-0G9DJq4dOAR0csY-tQ8EMVLLU8LBoBFccCFGAJbSfbYFA7FgLUn1YPCc4GLWXb6T01g%3D%3D&a=X)\n.\n\nForward-Looking Statements\n\nThis press release includes forward-looking statements intended to qualify for\nthe safe harbor from liability established by the Private Securities\nLitigation Reform Act of 1995. These forward-looking statements include, but\nare not limited to, statements about our plans, objectives, future targets and\noutlooks for our business, representations and contentions, and the outcome of\nour regulatory submissions, and are not historical facts and typically are\nidentified by use of terms such as \"may,\" \"should,\" \"could,\" \"expect,\" \"plan,\"\n\"anticipate,\" \"believe,\" \"estimate,\" \"predict,\" \"potential,\" \"continue\" and\nsimilar words, although some forward-looking statements are expressed\ndifferently. You should be aware that the forward-looking statements in this\npress release represent management's current judgment and expectations, but\nour actual results, events and performance could differ materially from those\nin the forward-looking statements. Factors which could cause or contribute to\nsuch differences include, but are not limited to, our restructuring of our\ndirect sales team and strategy in Germany, ability to successfully\nobtain U.S. FDA and Health Canada marketing authorization or approval, our\nability to reduce costs, optimize operations, and achieve cash-flow break-even\nin the second half of 2026, our ability to appropriately finance the Company,\nand the risks discussed in our Annual Report on Form 10-K, filed with\nthe SEC on March 30, 2026, as updated by the risks reported in our\nQuarterly Reports on Form 10-Q, and in the press releases and other\ncommunications to shareholders issued by us from time to time which attempt to\nadvise interested parties of the risks and factors which may affect our\nbusiness. There can be no assurance that the Company will be successful in\nmaintaining its listing of its common stock on the Nasdaq Capital Market. We\ncaution you not to place undue reliance upon any such forward-looking\nstatements. We undertake no obligation to publicly update or revise any\nforward-looking statements, whether as a result of new information, future\nevents, or otherwise, other than as required under the Federal securities\nlaws.\n\nPlease Click to Follow Us on Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=1442588769&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4593346-1%26h%3D84005167%26u%3Dhttps%253A%252F%252Fwww.facebook.com%252Fcytosorbents%26a%3DFacebook&a=Facebook)\n and X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=1444972509&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4593346-1%26h%3D3027793401%26u%3Dhttps%253A%252F%252Ftwitter.com%252FCytoSorbents%26a%3DX&a=X)\n\nU.S. Company Contact:\nPeter J. Mariani, Chief Financial Officer\n305 College Road East\nPrinceton, NJ 08540\nir@cytosorbents.com (mailto:ir@cytosorbents.com)\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/cytosorbents-announces-new-data-presentations-at-upcoming-international-conferences-in-cardiac-surgery-and-critical-care-302894072.html\n(https://www.prnewswire.com/news-releases/cytosorbents-announces-new-data-presentations-at-upcoming-international-conferences-in-cardiac-surgery-and-critical-care-302894072.html)\n\nSOURCE Cytosorbents Corp\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS693860/CytoSorbents-Logo.jpg?id=OA2978898\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn6TPKpZa-20260930","title":"CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care","author":"PR Newswire","ticker":"CTSO","created":"2026-09-30T11:00:02.859Z","tickers":["CTSO"],"exchange":"NASDAQ","article_body":"CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care\nPR Newswire\n\nPRINCETON, N.J., Sept. 30, 2026\n\nPRINCETON, N.J., Sept. 30, 2026 /PRNewswire/ -- CytoSorbents Corporation\n(NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in\nthe intensive care unit and cardiac surgery using blood purification,\nannounces upcoming data presentations using CytoSorb® in open heart surgery\nat the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting\nin Barcelona, Spain from October 7-10, 2026 and in critical care at the\nEuropean Society of Intensive Care Medicine (ESICM) Annual Congress in Lisbon,\nPortugal from October 10-14, 2026.\n\nUpcoming International EACTS and ESICM Conferences Highlight CytoSorb Use in Cardiac Surgery and Critical Care\nEACTS 2026\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=865241141&u=https%3A%2F%2Fwww.eacts.org%2F40th-eacts-annual-meeting%2F&a=EACTS+2026)\n is the world's largest cardiothoracic surgery conference, focusing on\nadvancements, innovations, and surgical techniques for heart and lung\nconditions.  The following data presentations highlight the use of CytoSorb\nin cardiac surgery:\n\nThursday, October 8, 2026:\n\n * Intraoperative Hemoadsorption to Reduce Bleeding in Isolated CABG under Dual\nP2Y(12) Inhibitor and DOAC Therapy\nProf. Michael Schmoeckel (Ludwig Maximilian University (LMU), Munich, Germany)\n * Hemoadsorption for Postoperative Vasoplegia: Real-World Data from the\nInternational Prospective COSMOS (CytOSorb® TreatMent Of Critically Ill\nPatientS) Registry.\nProf. Federico Papallardo (San Raffaele University, Milan, Italy)\n * Hemoadsorption to Reduce Hyperinflammation during VA-ECMO: Results from the\nInternational Prospective COSMOS Registry.\nProf. Federico Papallardo (San Raffaele University, Milan, Italy)\nFriday, October 9, 2026:\n\n * Improved short– and long–term outcomes in 'high–risk' heart transplant\npatients with adjunctive intraoperative hemoadsorption treatment – A single\ncentre's decade of experience\nProf. Endre Nemeth (Heart and Vascular Centre, Semmelweis University,\nBudapest, Hungary)\nESICM LIVES 2026\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=1068558133&u=https%3A%2F%2Fwww.esicm.org%2Fevents%2F39th-annual-congress-lisbon%2F&a=ESICM+LIVES+2026)\n is one of the leading international critical care conferences highlighting\nthe latest research, guidelines, and treatments in intensive care medicine.\nData from the COSMOS Registry will be presented by Prof. Ricard Ferrer (Vall\nd'Hebron Hospital, Barcelona, Spain).\n\nMonday, October 12, 2026\n\n * Liver Support with Hemoadsorption: Initial Report from the International,\nProspective COSMOS Registry\n * Hemoadsorption to Treat Hyperinflammation During VV-ECMO: Preliminary Report\nfrom the International COSMOS Registry.\nTuesday, October 13, 2026\n\n * Hemoadsorption for Postoperative Vasoplegia: An Analysis from the\nInternational, Prospective COSMOS Registry.\n * CytoSorb hemoadsorption as an adjunctive treatment in sepsis and septic shock:\nInsights from the first 200 patients included in the international,\nprospective COSMOS Registry.\nDr. Phillip Chan, Chief Executive Officer of CytoSorbents, stated, \"We are\npleased to see such a broad body of clinical data on CytoSorb accepted for\npresentation at two of the world's leading cardiac surgery and critical care\nconferences.  These presentations span important areas of unmet medical need\nacross cardiac surgery - including the removal of blood thinners, heart\ntransplantation, heart failure, and shock following open heart surgery - as\nwell as critical care applications such as acute liver disease, acute\nrespiratory distress syndrome (ARDS), and septic shock.  The latter is\nparticularly timely as Sepsis Awareness Month draws to a close and reinforces\nthe continued need for more powerful approaches like CytoSorb to help manage\nthe life-threatening hyperinflammation and organ dysfunction associated with\nthis devastating condition.\"\n\nDr. Chan concluded, \"We remain deeply committed to supporting high-quality\nclinical research and expanding the evidence base for CytoSorb across a wide\nrange of deadly conditions.  A cornerstone of this effort is our\ninternational, prospective, multicenter COSMOS Registry, which is designed to\nsystematically capture real-world clinical experience with CytoSorb across a\nbroad spectrum of critically ill patients.  By generating data on how\nCytoSorb is being used in everyday clinical practice - including patient\nselection, timing and duration of therapy, safety, and clinical outcomes -\nCOSMOS is providing important insights that complement controlled clinical\nstudies, help clinicians further refine and optimize CytoSorb therapy, and\nhelp to further establish the role of CytoSorb in the management of complex\ncardiac surgery and critical care patients worldwide.  We are excited to see\nthis growing body of evidence being shared with the international medical\ncommunity.\"\n\nAbout CytoSorbents Corporation (NASDAQ: CTSO)\n\nCytoSorbents Corporation\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=3361727760&u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D9JuP_ayC1LdGvZSRsWbpOcxv8qk6wGLsY2t00RIQUOzAH3VW97AvfsG_ahhmT0mys1Z7mMogHwGPt5_roawj-VjXMApe7mJPp3JTGiiEMRssOYDddfH8wccpgiHMCPcv-2cDU61vi58bwv5dHDhj7peoy1MZKZWlCXfz1_N9E3t0HjjPmVOwadc3qZ-Ve58qLcX37ZTHWslNYdMBkXhoIeyZXNyYDOo4OgcYt9s3LH6JIp5Q4wqFW8nd_3bcUoKKVTzA_KymPoJJgOppVrLNTA%3D%3D&a=CytoSorbents+Corporation)\n is a leader in the treatment of life-threatening conditions in the intensive\ncare unit and cardiac surgery through blood purification. CytoSorbents'\nproprietary blood purification technologies are based on biocompatible, highly\nporous polymer beads that can actively remove toxic substances from blood and\nother bodily fluids by pore capture and surface adsorption. Cartridges filled\nwith these beads can be used with standard blood pumps already in the hospital\n(e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal\nmembrane oxygenation or ECMO, and heart-lung machines), where blood is\nrepeatedly recirculated outside the body, through our cartridges where toxic\nsubstances are removed, and then back into the body. CytoSorbents'\ntechnologies are used in a number of broad applications. Specifically, two\nimportant applications are 1) the removal of blood thinners during and after\ncardiothoracic surgery to reduce the risk of severe bleeding, and 2) the\nremoval of inflammatory agents and toxins in common critical illnesses that\ncan lead to massive inflammation, organ failure and patient death. The breadth\nof these critical illnesses includes, for example, sepsis, burn injury,\ntrauma, lung injury, liver failure, cytokine release syndrome, and\npancreatitis as well as the removal of liver toxins that accumulate in acute\nliver dysfunction or failure, and the removal of myoglobin in severe\nrhabdomyolysis that can otherwise lead to renal failure. In these diseases,\nthe risk of death can be extremely high, and there are few, if any, effective\ntreatments.\n\nCytoSorbents' lead product, CytoSorb\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=3786967255&u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D9JuP_ayC1LdGvZSRsWbpORxGgG5d5RRi3BuX6LwmaJVAb04b6VxEP2rIDiYKjhRY5BGBnQuM6Q3kjTT1kfgmJGPxn9msqMZmf55jsQLSmKJgQTCQc49wvOWphERpmow-P87r7PViCzBb4Y1ZEzd5znEqmX1WUt1VTubl-o_XzoOUQxKPV1ejae2pzOWyPwo54Zr0G8HPM_KqCP8VP6Oi33ltMv4kDPIEX-iy4QoeMCsq3ZZr5KMFbJ6fBk9OngDF1tAOdFdSa6W_409-5F4-nFkP2EoLIZZPwTw-DKcZROoiFjY4tWzcmuV7qhq5LUUsQhRZ3ZAv9nDI97f4WQJ0zLoh4-r4UlAokT4cYtVx4F6tYd5dNSNSUb9Iyhc68l340zD8UOZt65d8NH0gcJyrO8V8lN3U2xWVmg3xmZPrdQM%3D&a=CytoSorb)\n(®)\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=293165892&u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DbaBPxM0OpouV4xBPdNuHYQfGlZzkY6K_qG46Q_IfgFR7arUisOobkA4cKQtSOQe-rOZwkkPdbDu0IgqPxsa3VLymjAokxa4qRMDc_fjcjL96L8-mdjI6ris1lWrtE8SBx43Dfm8nQT3BrsqC0kmhkT93ee-edDa032oIFBytvd__bccMenYfVeHvDkWY5G6WKhb_hAPt1ZDUOfDAHd_qY7W-sp6_0ILjoK7fshGy3IaCnVA6i42GWSj8gPbkimYNrkj5Qbsv4HWv0gIxibWQdHL8pgVjyUx-Eji5ostWKueYyoNF80xmsKMYMH5wRWhD2ggm8zuuzSXYU3SqdBRRB9LgsaCixpvGzMWcWwkEzfhQr32x4ogyvmWyS2yz0UfUE1F25JKP8VQFnxtCNIPX0zmBswRbttO6WNcl5IzNMKs%3D&a=%C2%AE)\n, is approved in the European Union and distributed in over 70 countries\nworldwide, with more than 300,000 devices used cumulatively to date.\nCytoSorb was originally launched in the European Union under CE mark as the\nfirst cytokine adsorber.  Additional CE mark extensions were granted for\nbilirubin and myoglobin removal in clinical conditions such as liver disease\nand trauma, respectively, and for ticagrelor\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=135522112&u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DBevZEUStHG2IGGo9anAX_kSPtnFrGz8ipiosqgiTXfKw3qMh-1zNEzD9J5E3RekPKCTE-y4C_wqlKR9OVFfNam6JivDoyEJq9TOmJbNtSM_s6u3J0KUzy0xeXAWsqydOQ92QyjhKhSinO6Gc7atcfWLADoAceyiakLu2G9QTXTlVw0OZwXiMVuyw7Cs-Ecaz0s1_fAOQaCqgeR_nCsu6Zx-7NNBmsaCYsctLsuJFh6ZJcKCFc2ZLMBH7fwvz3WQicCKLtGj29GVMBG0NasMP1FD47T7pPJz7HryVVqXdT-h7Sn515aPzGZT_cxLdRgbbvTKHF-jIiK6hN6KhFTcqs4Y-1XZADWNIKvQ7kCz-4_WrHaFKEkeE5YzTV-37oek5advSjnyuNsq6CLS3ObvS25khvux6rg-8msBJ6R6ULEUzdbyR0PTYCvqYvA8M9Y9H9dIRNnh27YgzCedTKhdDRm3tJCxmTnyRgYJ_TiUP92_ildMETnXAexElnRbsADbkpbOMOBgpXDEEuc1aySo2TEC91JyCM_BOZF3bHq5PjpP2vK1phXPmYaA8gKD6To0oPdzHfOKEEnHMLxeq_8McvrH-KoanI3LwVurLwV4IDBZm1okXjoQB81Tktr3F2hn7AlqVJsyy4wf3-OBbwxlLtN4my1RtRykA6CaYvX2b0HeDuPBOeXvrKlvOrgcUQYvUsICM9i63gvrVBV11PTn1_EgnEwV-qgj3_iEuoqsE-F8qDFpRwl4N7R4Ob8L_-ApAZrNVNIofvB5oDpym63X0Aw%3D%3D&a=ticagrelor)\n and rivaroxaban\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=2712168254&u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3Dp47WrgYj8pmjYpAToXFgCBnYjnYobpTSHcu-db0NjHxVTyhpykBGcN6QCaM1R6hx33XBIndzInv4GO1RZoDg9SgJvKPmJjB6r7Kr9oCGCUVfQAWl_WP2JV8PblJXBmgLZfQk4cji55Tzbj3rMvIqVx-RNfHAwpxZPcsXWYxIbsAO4mHmlB0-RdTJDSrpZr20lyzVVmV7jh2CY7xvKtyPo6q4DNWunLrC6S5nYmqReatahfVYT6XMCCk1Y-jIv--09ysz652OrQbnfPGBOpeldNxKRA2uzZReWbvfOnn3rNsQ4QbXvXOf2DwvJWVo2JWl05tCR7JQvF87Tt00bLnfiYdmrFJegNei1CwN-G-poPHXnzp3tajndqz7lUxgs9rh8yWvU41XhRN9PyPJnkBsckHMSEDiH9uwP8g5cTQ_DPKcSwfMBo0S_Z32D0qqrdGUfE3HecdsgOanxffcpBxZOVb6_ONPyJLBB81v7of7Mcnl2U8zG4bPvikILAbdljD5dpWIvxsSk8eYN_wwAGPVwuIlEKsQDg2zUFzoWptwzTXKscjE68FBj6kM8t_9tGMCf4MoNIojWGsdX00wasx2K8c46_ig0E-RcxGAIa_ce4VQ42L_7ehyeaNlrtoZjqm5gJf1c5-UMIZ4qPtRt-GOt0-NqGzlWIesspUjNBnm9b2dZHDFzHbIYkSk_qk8BALJzyV9SiiuXog-OmC075Pgt1Qb586C-c4tf-aV9zFBey0X3bmJKxjeYES8bEziGcia7MK85FFCxPFbl7K6njmB5gHvTro8Qm3RoaxO0rsE8CaOcc3bdCFZGEJiSFPq4c-k&a=rivaroxaban)\n removal in cardiothoracic surgery procedures. CytoSorb has also\nreceived FDA Emergency Use Authorization\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=307639980&u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3Dm2FNhPcJgHNCmRfLJVv2QaAW1tb2zXDzuMyJsT4OyY05SQFzpVg7VpryNSG_1ORQ3MnpsEhyG8-uJcHJwbmf-YrAF0xdBIjMjHeE_-RbhLlxJXUYoNTG7-i2BFq6mE_3BR9lM-cyxeoPxQ8HSRVpEKZnFLf2iMp_EAjk81MLks2pp3BEPxXDg7GB8hWbWqmyEKPPOGyLg6KcQEgnq1mE-lYmkOWcZTQGWHRs7hyQeCWvm8wzHp7_-0t-GCiKaMhT76JaGuu8StI7n8bXuFfDHzO-k09EXhw5KftVKx3rGA1oeNE-oi4X3-sUrSW66jed-XUIzr5kbb6BlqcnHnShdWzbWUpSyr4Z-HGvs6H9gxx_IsW6S-XdIlg9fhtZbGNHDXyVeGym1Zgymgr16oO2XAO58RAP1-TM5pq9kjItAFFm6yDMHNv4d72c93d8jNMcSaKg2WquKvQNApj68hp_p-C69ojr1P7JX4lnHeVSFp2gJO2IdQoNBHu8TNMiQHrZXAobag-FEX0EaUdsb6S9ZJaTaZb3e4BNlN7Ae40qnjQgonSqF4K185b-ayMm3GuU02bsTFvdQZngRu65EqfK1MibhcuQXEv4-nulswtMGJsmLW7iMPrOuYHXkmZKwzn1WBMWaviYa8t9K_AvB7dkkEW7OrNN-bAhwG1tyoz695kAOwdnL0yEGS0LjB8bxDFivx-X7ZE8XzdwDP7UXuF2GonsCc1MWlwUskFiMZDFgYjg1mvJy3q3FA8V5amSK3jlJ-3DAvrirP9meVVBdXETJZ75k3u7SSgVstNgfmdVujRiw8Lx0j1Q9pnLI3nUv-BJ&a=FDA+Emergency+Use+Authorization)\n in the United States for use in adult critically ill COVID-19 patients\nwith impending or confirmed respiratory failure.  CytoSorb is not yet\napproved or cleared in the United States.\n\nIn the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR\nantithrombotic removal system, an investigational device based on an\nequivalent polymer technology to CytoSorb, to reduce the severity of\nperioperative bleeding in high-risk surgery due to blood thinning drugs.  It\nhas received two FDA Breakthrough Device Designations\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=1252299118&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4492043-1%26h%3D2476011309%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4484224-1%2526h%253D3712982973%2526u%253Dhttps%25253A%25252F%25252Fwww.globenewswire.com%25252FTracker%25253Fdata%25253DOVYNYVfVfZTwSB92O9_yJfhu9YsEcpW6lg6ML5vFCptxR44HDP4r6iT5zmJIIfYbxtpoGxotkZNp5WaA2UFp1BzONSEbP-JnxHDsgt_gqku1bWgZzGxpI6Bxy8IHho1GqBkd8dOKS5U2dX7yTgyMHhBD0fGGQ7lczyR_AZk-JS7x-pT_Bqfb2q2MCuc_Qt2Mgs9FkyR_XSHYG4OWBARA8nhLNtL_SvM9NL2O5rGboN8Krvuu6TNd02rb6wNKMfGErajMJbU8hamDo_tF2JVs7N27aOWiotz4FJeXcF4bPQVVdJPKLH9egCJziSVHtGjwWhwaKw1EU9j3QZ5Bj2AHo97lCl2HlB61jk9tcuabeb6hR2hJ_ugB8WUJ83E8XMXRqYvo6LvvS5HBmfJqo_vB2_yXUFwd0yCbRXiT6L0CCDpPZ1f46lUOhY7z1OhPY7_1VYEgMEZEvF7tYM08bZal17zyoqqedwkMRD4RQXmtNHMkc8_ydS4LtafjfDjtmlL6HPVYSK2x1Gt8Dm7Fv3yq4jEVuaYH2nwTMW_K7xatC6REaGB7565Mrg874XTgtGVJAWShOhSnFlTENjl80p9FSbQ54XiM9dN2w8IU9C5NAZbkXBtmLIkAcPO9EhMzW7AMp9nYsnXUBV3_iPoGb6tI-x6ytgcXVvacsFcOxZ2SGuKaRZUGawbo3Zx0R-E2rV5wkF2ckzdhToMrrBMGUNNTNfrR0geKm1pP2Sg8gDIz_SLTC6s10f6OOfVZutP_5a2dw66GfdjNZZZASjInAJRph3BAEbwo-4tb76befGMf1IDNhIXOvxRIOmULbFbaBemQ_wN52soeFXg5vuB1PCk5udsH_J8jD4brC_t_E_UNh-sSAQzUyp7x0fXOvc55-jPBVJC_KCp5TiTEpdI2j_vXLqzKS_PmazRaGRzVE9ItMAsNXP4mP4AHMf7oenhGU282VnKAcErxSOMWrkGwOhs2XjM6EU5ux5yK1n8jMGmyaSfoAQOpybL1IClQ0_e1r6zu%2526a%253DFDA%252BBreakthrough%252BDevice%252BDesignations%26a%3DFDA%2BBreakthrough%2BDevice%2BDesignations&a=FDA+Breakthrough+Device+Designations)\n:  one for the removal of ticagrelor\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=579167168&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4492043-1%26h%3D2072534648%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4484224-1%2526h%253D182667382%2526u%253Dhttps%25253A%25252F%25252Fwww.globenewswire.com%25252FTracker%25253Fdata%25253DBevZEUStHG2IGGo9anAX_sK9FUmyXMo-P_MG36LpTYuG9ZUwyu7QHdXrf2ZKHbGYg4QNgsvM_gaUcmF5yklQp76iKyqOa_ddZRkBt2kRe7sC5GMbetFomKR2KWFAWOFoY5jNT4U3DHMBT9NHx4j8yO6EzDGETQTIpUmMFGySVexqa4A_PbM6jaQzEkluS4lZYntV9NN4bXRs4SPlEwUSqXroetgS_yayRqGOBHOLstwRhaFyXWcCHd4inwMm54ZE31Rmz8dBZgdcu-BRspFBE3akThhcKY0gBTYBYVSHjnCdAo5qmkv8hkWMY2G5hXVRZm2JYyraZMssywdnVF5F0CHpRAFwGEwMWE2Njj1Pt52Mo1lc3INMrhBmWDA-NmC9LEA9QwqVa46A60NbMod6s4hqQLotRCWof5KZglqdYXgC6aGeQ6hTa1ayTsYgzwiGk_tMsWUj525w4lLPPmgf3VVfvQXMrMt02b_zkMIHbZl1seiYnLx2OZZ8Dkfmzj6RtxYGZRXDgXDUE1iuVy6f0pDPoydYexYuEUvNsJ_kE99TyDpaDGuNZbtnqjCukU_X2uFDD3coXNrgGLPa-uRL3fB9B3ko7V2dTDgIZWilIpIgnatnUA-4w8Q4Dr5ZMTLqejY18puoTORponx08v437S2gIJE-PFee2zYXeJVYsfLoi5sFzFWqsrbHCHKnSJsSawGpFpdW7GT7C0rIeSwiAKlIrBE9eAQqsM-G8I70LyU6MZ2Suywae6f4rmyG6ZTAsB29xoKVR_RyrC-m4Yb8gvmrsfx4IVU0MW5MSq6lFQAX-rHR0c1yFB1abbOb3H97_ZvJC8ZJIDgiE61FVI0ehagjW7Q1rS51KqAqxNasQWSq-BaxNEeYLSrrFU552ZZD_-eKvUwlqhE7ivtmz05hiw%25253D%25253D%2526a%253Dticagrelor%26a%3Dticagrelor&a=ticagrelor)\n and another for the removal of the direct oral anticoagulants (DOAC)\napixaban and rivaroxaban\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=2175267183&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4492043-1%26h%3D1768743861%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4484224-1%2526h%253D2278238800%2526u%253Dhttps%25253A%25252F%25252Fwww.globenewswire.com%25252FTracker%25253Fdata%25253D2qt5UxRbkefI_XwOXSqhA9q3FRJO4rv6H0__RAcvJtHWtIQeDwRE9RPGavd8-FcYqZAgy_vbeVwCWXlW4lGJ4ToTpGPq7AbbAEEKKGQFf8Pdg0EL0Dx0dn-5MH54wYgpVDUNT_RVHrdrj2dNiGCcPyOI3Lt5dUauPucTliFxodbC_ilzsO0qoWvBDY86aPH9s5HiXIvDP0Q0pcaILyeq3SvA2rhfo5M8oKbPGxwf7yajJBkQBKDyO0snrFWdLSh4fUlwEQMAIkSsYc48fSYvt21Ow3ljvmtUsSzZYqxvaEcS4qtaYXp0ztWd56XLVcLdE16GKjuBg3O9t6JeazAcWikCLHUBhbGxLKlkjaGZ-Edj0uxCOsC2fivgDUmid_d3N7IxMdopzznesT-Puyq3hZnwwG9J_UBQRWLfxuoqb1skPw5MSYR0J4izvHJkaUnuojNOdvQONtb_sIujI7A2hDFwbj0WODj7OprKHLDzNqRgw6T3MFRNWPGXTpxABWqWZ_GbEgUnF4kKfOmruUrVicFcpNWuyKrYS2a_mRDxZVjLF-VX8jmYe2mJ4n43H6ybnzFk8XeLxYBXaSzHdObYs6y9dkJ8Hwo5CrhKLznklX7DdoPvRyLY2xrnJf2dXIVyd03Wmsk0aOHffU_F8Z4fDkOjA97HQT11yVdReAcr1BwPS4pYPw2u5mKIsQlHd3OilyMVLfUQoie7mDUiLFns-CrIEoQ-mXDgoNulMDoIndvua3-dc8b6McLa5djidyYox4GWjovVTu_Beu0m0mt-6BsEFyKKURkmSdQe0uq78VtRdp9cBry4n-LRHcUz35dC-RfbEo7HL2dHS4CLnhn4KBfhCDpty6ukqhF5AbHxP9P39TM5_jbFrbNcdJ0USCdjUfwaHgzD0tali0mjBesnBtNG29aG2ikR1HPAW1fbouxtF9CsD-qhJ0KSiGRoL_avZDZI2DN3u7vn5c2NVazCMWATGVqOza8umQ_r0u4tCdv3qfrreEYDshwRLyJuIu5b7Uy1sB0dERGVHnML3KGewYgO6Sb-bpEEyL_HuQAKe17KsHeEERmwmrFKQs5iXv2IWU2u8cWQVOGEsD-4wms94t5gnUD2vt7RH1UcuyjYq9cwIpz7Y34pSY5RL_FBk69QJ4GnKifnRu8ggIK4Is_l20ecwTdmPyOQVqWcmNnu_AYYwpSRIHPT6sLK3M4BTSlnzmuTQywWbmDCJ_494lng6rZ_X_3wgSRqvhz6iRtOChA%25253D%2526a%253Ddirect%252Boral%252Banticoagulants%252B(DOAC)%252Bapixaban%252Band%252Brivaroxaban%26a%3Ddirect%2Boral%2Banticoagulants%2B(DOAC)%2Bapixaban%2Band%2Brivaroxaban&a=direct+oral+anticoagulants+(DOAC)+apixaban+and+rivaroxaban)\n in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery.\nThe Company is actively pursuing regulatory approval of DrugSorb-ATR with the\nU.S. FDA and will pursue regulatory approval with Health Canada with better\nvisibility from the FDA.  DrugSorb-ATR is not yet granted or approved in\neither the U.S. or Canada.\n\nThe Company has numerous marketed products and products under development\nbased upon this unique blood purification technology protected by many\nissued U.S. and international patents and registered trademarks, and\nmultiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™,\nHemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™,\nContrastSorb, PuriFi®, HotSwap®, and others. For more information, please\nvisit the Company's website at https://ir.cytosorbents.com/\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=1468745960&u=https%3A%2F%2Fir.cytosorbents.com%2F&a=https%3A%2F%2Fir.cytosorbents.com%2F)\n  or follow us on Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=1391433662&u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DsB2AG7X4Z43BoIDfgybXOhtx6hajGmLFRYdf-CJkEqF3K0BxaD2m7c_NZkYwFsYeNOY-LK22UCYVjieKWHZcgsLvVcrOalL0DfCSkqBZ2R_uGHEIFHLoP0BQqxUZI_ekbspxc47A02TOAJxuUO_K9TZyQwpeGoQum9SjiTg36Arl4PtOgWHHT25tP3a7Ym1EB8iQrlZmSYoiowd-zHbIFTmyj_pRohZ2MNAXPml_QnQFTso55cgXNSvoEGmuwOjL&a=Facebook)\n and X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=4098877400&u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DKRERF9IW2qXW13jmGfo2v9T8dZnx2rVmbAIsoapwSyctLh6P5jlWX3C4X5SXqbzb0GaZHZ5_z5G5t0Zl0IzRFWQlon1TY5bfeIRgjKiElxVuahzWnjosldeOn5JOUPxhCbumHzexqM_fZKIwMl-0G9DJq4dOAR0csY-tQ8EMVLLU8LBoBFccCFGAJbSfbYFA7FgLUn1YPCc4GLWXb6T01g%3D%3D&a=X)\n.\n\nForward-Looking Statements\n\nThis press release includes forward-looking statements intended to qualify for\nthe safe harbor from liability established by the Private Securities\nLitigation Reform Act of 1995. These forward-looking statements include, but\nare not limited to, statements about our plans, objectives, future targets and\noutlooks for our business, representations and contentions, and the outcome of\nour regulatory submissions, and are not historical facts and typically are\nidentified by use of terms such as \"may,\" \"should,\" \"could,\" \"expect,\" \"plan,\"\n\"anticipate,\" \"believe,\" \"estimate,\" \"predict,\" \"potential,\" \"continue\" and\nsimilar words, although some forward-looking statements are expressed\ndifferently. You should be aware that the forward-looking statements in this\npress release represent management's current judgment and expectations, but\nour actual results, events and performance could differ materially from those\nin the forward-looking statements. Factors which could cause or contribute to\nsuch differences include, but are not limited to, our restructuring of our\ndirect sales team and strategy in Germany, ability to successfully\nobtain U.S. FDA and Health Canada marketing authorization or approval, our\nability to reduce costs, optimize operations, and achieve cash-flow break-even\nin the second half of 2026, our ability to appropriately finance the Company,\nand the risks discussed in our Annual Report on Form 10-K, filed with\nthe SEC on March 30, 2026, as updated by the risks reported in our\nQuarterly Reports on Form 10-Q, and in the press releases and other\ncommunications to shareholders issued by us from time to time which attempt to\nadvise interested parties of the risks and factors which may affect our\nbusiness. There can be no assurance that the Company will be successful in\nmaintaining its listing of its common stock on the Nasdaq Capital Market. We\ncaution you not to place undue reliance upon any such forward-looking\nstatements. We undertake no obligation to publicly update or revise any\nforward-looking statements, whether as a result of new information, future\nevents, or otherwise, other than as required under the Federal securities\nlaws.\n\nPlease Click to Follow Us on Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=1442588769&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4593346-1%26h%3D84005167%26u%3Dhttps%253A%252F%252Fwww.facebook.com%252Fcytosorbents%26a%3DFacebook&a=Facebook)\n and X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4786305-1&h=1444972509&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4593346-1%26h%3D3027793401%26u%3Dhttps%253A%252F%252Ftwitter.com%252FCytoSorbents%26a%3DX&a=X)\n\nU.S. Company Contact:\nPeter J. Mariani, Chief Financial Officer\n305 College Road East\nPrinceton, NJ 08540\nir@cytosorbents.com (mailto:ir@cytosorbents.com)\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/cytosorbents-announces-new-data-presentations-at-upcoming-international-conferences-in-cardiac-surgery-and-critical-care-302894072.html\n(https://www.prnewswire.com/news-releases/cytosorbents-announces-new-data-presentations-at-upcoming-international-conferences-in-cardiac-surgery-and-critical-care-302894072.html)\n\nSOURCE Cytosorbents Corp\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS693860/CytoSorbents-Logo.jpg?id=OA2978898\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-30T11:00:03.91563925Z","server_sent_at_ms":1790766003915},"received_at":"2026-09-30T11:00:03.966Z","source_url":"https://www.prnewswire.com/news-releases/cytosorbents-announces-new-data-presentations-at-upcoming-international-conferences-in-cardiac-surgery-and-critical-care-302894072.html"},"analysis":{"id":"145168","press_release_id":"156480","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["Forward-looking statements note restructuring of German direct sales team, Nasdaq listing maintenance risk, and dependence on achieving cash-flow break-even in H2 2026"],"eventType":"operations_update","narrative":"CytoSorbents announced multiple accepted data presentations using CytoSorb at the EACTS Annual Meeting (Oct 7-10, Barcelona) and ESICM Congress (Oct 10-14, Lisbon).\n\nPresentations cover cardiac surgery uses such as blood-thinner removal, heart transplant, and postoperative vasoplegia, plus critical care uses including liver support, ECMO, and septic shock, largely drawing on the international COSMOS Registry.\n\nCEO Phillip Chan framed the broad acceptance as reinforcement of CytoSorb's growing real-world evidence base across areas of unmet medical need.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Conference calendar update -- watch COSMOS Registry presentations at EACTS/ESICM for incremental real-world CytoSorb data, not a new clinical or regulatory event."},"keyFigures":{"customDimensions":{"cosmos_sepsis_cohort":"first 200 patients","countries_distributed":"over 70","devices_used_cumulative":"more than 300,000"}},"quotedText":"We are pleased to see such a broad body of clinical data on CytoSorb accepted for presentation at two of the world's leading cardiac surgery and critical care conferences.","namedEntities":{"people":[{"name":"Dr. Phillip Chan","role":"CEO of CytoSorbents"},{"name":"Peter J. Mariani","role":"CFO of CytoSorbents"},{"name":"Prof. Michael Schmoeckel","role":"presenting investigator, LMU Munich"},{"name":"Prof. Federico Papallardo","role":"presenting investigator, San Raffaele University"},{"name":"Prof. Endre Nemeth","role":"presenting investigator, Semmelweis University"},{"name":"Prof. Ricard Ferrer","role":"presenting investigator, Vall d'Hebron Hospital"}],"products":["CytoSorb","DrugSorb-ATR","COSMOS Registry","ECOS-300CY","CytoSorb-XL","HemoDefend-RBC","HemoDefend-BGA","VetResQ","K+ontrol","ContrastSorb","PuriFi","HotSwap"],"companies":[{"name":"CytoSorbents Corporation","ticker":"CTSO","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Announcement of upcoming conference data presentations for CytoSorb, including real-world COSMOS Registry data. It modestly supports the evidence base but contains no new clinical results, revenue, or regulatory decision."},"tickerRelevance":{"others":[],"primary":"CTSO"},"globalImportance":14,"audienceRelevance":18,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"conference-presentation-calendar","sectorWeight":"medical-devices","issuerAuthored":true}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"CytoSorbents announced multiple accepted data presentations using CytoSorb at the EACTS Annual Meeting (Oct 7-10, Barcelona) and ESICM Congress (Oct 10-14, Lisbon).\n\nPresentations cover cardiac surgery uses such as blood-thinner removal, heart transplant, and postoperative vasoplegia, plus critical care uses including liver support, ECMO, and septic shock, largely drawing on the international COSMOS Registry.\n\nCEO Phillip Chan framed the broad acceptance as reinforcement of CytoSorb's growing real-world evidence base across areas of unmet medical need.","key_figures":{"customDimensions":{"cosmos_sepsis_cohort":"first 200 patients","countries_distributed":"over 70","devices_used_cumulative":"more than 300,000"}},"named_entities":{"people":[{"name":"Dr. Phillip Chan","role":"CEO of CytoSorbents"},{"name":"Peter J. Mariani","role":"CFO of CytoSorbents"},{"name":"Prof. Michael Schmoeckel","role":"presenting investigator, LMU Munich"},{"name":"Prof. Federico Papallardo","role":"presenting investigator, San Raffaele University"},{"name":"Prof. Endre Nemeth","role":"presenting investigator, Semmelweis University"},{"name":"Prof. Ricard Ferrer","role":"presenting investigator, Vall d'Hebron Hospital"}],"products":["CytoSorb","DrugSorb-ATR","COSMOS Registry","ECOS-300CY","CytoSorb-XL","HemoDefend-RBC","HemoDefend-BGA","VetResQ","K+ontrol","ContrastSorb","PuriFi","HotSwap"],"companies":[{"name":"CytoSorbents Corporation","ticker":"CTSO","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-30T11:00:22.936Z","global_importance":14,"audience_relevance":18,"importance_components":{"tickerTier":"small-cap","eventGravity":"conference-presentation-calendar","sectorWeight":"medical-devices","issuerAuthored":true}},"durationMs":6306,"modelName":"glm-5.3-flashx"}}